Clinical Trials on Cystic Fibrosis of Pancreas in Norway

Total 24 results

Oslo University Hospital

Recruiting

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

Cystic Fibrosis in Children

Norway
Haukeland University Hospital

Completed

High Volumes of Hypertonic Saline and Chest Physiotherapy in CF Patients

Cystic Fibrosis

Norway
Oslo University Hospital

Completed

Pre-flight Evaluation of Adult Patients With Cystic Fibrosis

Cystic Fibrosis

Norway
Haukeland University Hospital
University of Bergen

Unknown

Exocrine Pancreatic Function Testing in Cystic Fibrosis

Cystic Fibrosis

Norway
Oslo University Hospital
University Hospital, Akershus; The Norwegian Resouce Centre for Cystic Fibrosis and other collaborators

Completed

Cystic Fibrosis and Fit-to-Fly (CyFF)

Lung Diseases | Cystic Fibrosis | Hypoxemia

Norway
Clavis Pharma

Completed

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Advanced Adenocarcinoma of Pancreas

Norway, Belgium
Karolinska Institutet
European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Enrolling by invitation

NETwork of Linoleic Acid Supplementation in Cystic Fibrosis (NETLACF)

Cystic Fibrosis

Poland, Italy, Norway, Sweden
Rigshospitalet, Denmark
Cystic Fibrosis Foundation

Completed

Scandinavian Cystic Fibrosis Azithromycin Study

Cystic Fibrosis

Denmark, Norway, Sweden
AlgiPharma AS
Eurostars; Smerud Medical Research International AS

Completed

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984)

Cystic Fibrosis

United Kingdom, Denmark, Norway, Germany, Sweden
Oslo University Hospital

Completed

Prophylactic Fenestration of the Peritoneum in Kidney Transplantation (PROFFEN)

Incidence of Symptomatic Lymphocele After Kidney Transplantation | Prevalence of Perirenal Fluid Collections at One, Five and Ten Weeks

Norway
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, Taiwan, United Kingdom, Germany, Spain, Israel, Romania, South Africa, Korea, Republic of, Australia, Canada, Hungary, Ireland, Latvia
Haukeland University Hospital

Completed

Hand Therapy or Not Following Collagenase Treatment for Dupuytren's Contracture?

Dupuytren Disease of Palm and Finger, With Contracture

Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Symbollon Pharmaceuticals

Unknown

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

Pain | Fibrocystic Disease of Breast | Fibrocystic Changes of Breast | Fibrocystic Mastopathy

United States
Danish Breast Cancer Cooperative Group
Danish Cancer Society; Danish Center for Interventional Research in Radiation...

Recruiting

Partial Breast Versus no Irradiation for Women With Early Breast Cancer

Pain | Death | Scar | PROMs | Telangiectasia | Local Neoplasm Recurrence | Distantly Metastatic Malignant Neoplasm | Fibrosis Breast | Depigmentation/Hyperpigmentation of Skin

Denmark, Sweden, Norway, Chile
OncoC4, Inc.
National Cancer Institute (NCI)

Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)

Cervical Cancer | Small Cell Lung Cancer | Adenoid Cystic Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Melanoma | Pancreas Cancer | Metastatic... and other conditions

United States, Australia
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States

Clinical Trials on Cystic Fibrosis of Pancreas in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations